Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection.

In this issue of Gastroenterology Clinics, Guest Editors M. Nedim. N. Ince and David E. Elliott bring their considerable expertise to the topic of Gastrointestinal Infections. Top experts in the field cover key topics such as Candida esophagitis, Acute bacterial gastroenteritis, Clostridium difficile infection and antibiotic-associated diarrhea, and more. - Provides concise and comprehensive coverage of the issues physicians face every day. - Presents the latest information on a timely, focused topic under the leadership of experienced editors in the field. - Contains 14 relevant, practice-oriented topics including Helicobacter pylori infection; Viral gastroenteritis in special patient populations; Rare causes of hepatitis; Postinfectious irritable bowel syndrome; and more.

Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection.

In this issue of Diagnosis and Treatment of Gastrointestinal Cancers, guest editors Drs. Marta Davila and Raquel E. Davila bring their considerable expertise to the topic of Diagnosis and Treatment of Gastrointestinal Cancers. The early detection, diagnosis, and accurate staging of GI cancers, along with enhanced imaging techniques, new therapies, and a greater understanding of GI tumors at the molecular level, has revolutionized the approach to GI cancer patients in recent years. In this issue, distinguished authors recognized internationally as leading authorities in the field provide an exhaustive review of the latest topics in GI cancer. - Contains 13 practice-oriented topics including management of Barrett's esophagus and early esophageal adenocarcinoma; familial pancreatic cancer; colorectal cancer: screening and early detection; the microbiome in gastrointestinal cancers; and more. - Provides in-depth clinical reviews on diagnosis and treatment of gastrointestinal cancers, offering actionable insights for clinical practice. - Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

This issue will be an informative treatise on gastroparesis, a symptomatic chronic disorder of the stomach characterized by delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis is an increasingly recognized and diagnosed disorder. Treatment can be challenging due to several mechanisms which play a role in causing the symptoms. Symptoms of gastroparesis are variable and include early satiety, nausea, vomiting, bloating, and upper abdominal discomfort. These symptoms can range from mild to severe leading to such complications as malnutrition, functional disability, and multiple hospitalizations. The three most common etiologies are diabetes, post-surgical, and idiopathic (unknown). Treatment consists of dietary manipulation, medical, and surgical therapy. The articles will provide a comprehensive review and in-depth information on gastroparesis. Each chapter will be written by an expert in the area. This issue will give the reader a better appreciation for the breadth of gastroparesis.

A thorough update is presented by the Guest Editors on the diagnosis, treatment, and management of Barrett’s Esophagus. Not only do they address the most pertinent clinical issues like screening, biomarkers, surveillance, therapeutics, and predictors of disease progression but they present state of the art material on therapeutic/treatment modalities like EMR, ESD, and ablative therapy. Further, articles are presented on epidemiology, molecular pathogensis, and cost-analysis studies so that the reader will come away with a comprehensive update on Barrett’s Esophagus.

This issue of Gastroenterology Clinics of North America is all about acute upper GI bleeding and is divided into two distinct sections: section I is devoted to nonvariceal upper GI bleeding and section II is devoted to variceal upper GI bleeding. Acute nonvariceal upper GI bleeding may originate from the esophagus, stomach, or duodenum, essentially anywhere proximal to the Ligament of Treitz. In Section I, Dr Gianluca Rotondano, Hospital Maresca, Torre del Greco, Italy, begins with a review of the epidemiology and diagnosis of acute nonvariceal upper GI bleeding. We then turn to patient presentation, risk stratification, and how to initially medically manage these bleeding patients. I am pleased to have one of our emergency medicine colleagues, Dr Andrew Meltzer, Department of Emergency Medicine, George Washington University, contribute this important article and provide a unique viewpoint from the emergency department where most of these patients initially present. As we all know, endoscopic hemostasis is the accepted standard of care for patients with acute nonvariceal upper GI bleeding. Moreover, peptic ulcer bleeding is the most common nonvariceal cause of acute upper GI bleeding; thus, Drs Yidan Lu, Yen-I Chen, and Alan Barkun from McGill University, Montreal, Canada, provide an in-depth review of the endoscopic management of peptic ulcer bleeding. Drs Eric Tjwa, I. Lisanne Holster, and Ernst Kuipers from the Erasmus Medical Center University Hospital, Rotterdam, The Netherlands, review the endoscopic management of all other causes of acute nonvariceal upper GI bleeding, and in addition, Drs Louis Wong Kee Song and Michael Levy from the Mayo Clinic, Rochester, Minnesota discuss emerging endoscopic hemostasis treatments, such as topical sprays and over-the-scope clipping devices. Although endoscopic hemostasis is very highly effective, there are unfortunately cases where bleeding is unable to be controlled or when significant rebleeding occurs that is not amenable to endoscopic therapy. Therefore, I have included two articles that provide insight into the question...what if endoscopic hemostasis fails? The first article, written by Drs Philip Wai Yan Chiu and James Yun Wong Lau, from Prince of Wales Hospital, The Chinese University of Hong Kong, focuses on tried and true surgical treatment options. The second article, by Dr Sujal Nanavati, University of California at San Francisco, Department of Radiology and Biomedical Imaging, addresses the alternative treatment strategy of angiographic embolization, which has now emerged as the often preferred salvage treatment strategy.